<DOC>
	<DOCNO>NCT01020864</DOCNO>
	<brief_summary>This open , multicenter phase II study . The purpose demonstrate efficacy cetuximab combination carboplatin vinorelbine second line treatment patient recurrent metastatic head neck cancer progress treatment first line cisplatinum .</brief_summary>
	<brief_title>Cetuximab Combination With Chemotherapy Patients With Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically verify squamous cell carcinoma head neck curatively intend local treatment possible . Measurable nonmeasurable disease . Disease progression first line palliative chemotherapy cisplatinum patient recurrence &lt; 6 month primary concomitant chemoradiotherapy cisplatinum . WHO Performance Status 02 . Age ≥ 18 year . Neutrophil count ( ANC ) ≥ 1.5 x 10^9/l platelet ≥ 100 x 10^9/l . Normal liver function bilirubin &lt; 1.5 x UNL ( Upper Normal Limit ) , UNL ALAT liver metastasis . Creatinin clearance ≥ 50 ml/min . Signed informed consent . Other active malignant disease . Patients consider unable follow treatment plan followup visit . Other serious disease ( e.g . severe heart disease , myocardial infarction ( MI ) within 1 year , active infection ) . Any condition treatment opinion investigator may expose patient risk may influence purpose trial . Pregnant lactating woman . Known hypersensitivity towards one component treatment . Prior treatment either cetuximab inhibitor EGFR .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Platinum-resistent head neck cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Navelbine</keyword>
	<keyword>Phase II trial</keyword>
	<keyword>Combination chemotherapy</keyword>
</DOC>